Membership Directory

TheraGenetics, LTO

Category: Human Diagnostic Development
Phone: 44 (0) 207 848 0646
Website: http://www.theragenetics.com

TheraGenetics Ltd. is a Personalised Medicine Diagnostics Company focused in the prediction of response and side effect to medications for Central Nervous System (CNS) disorders. Founded in April 2006, TheraGenetics is a spin-out company from the Institute of Psychiatry, King’s College London. The technology is based upon 15 years of research into the pharmacogenetic investigation of CNS medications. The TheraGenetics founding academics developed the world’s first pharmacogenetic test for response prediction in psychiatry. TheraGenetics is now developing a portfolio of tests for CNS treatment individualization; matching the medication to the person. TheraGenetics goal is to bring pharmacogenetic diagnostics to the bedside in clinical care, drug development and clinical trial settings. Our target disorders include schizophrenia, depression, bipolar disorder, anxiety disorder and ADHD. TheraGenetics has an expanding IP portfolio in these areas. The company is led by Chief Executive Officer Richard Kivel, an experienced life sciences entrepreneur, and Chairman of the Board Dr. Heiner Dreismann, the former President and CEO of Roche Molecular Systems. TheraGenetics completed a £3 million ($6 million) Series A venture financing round in June 2007. This funding is being used to expand the team, establish new key partnerships in the commercial and academic settings and to accelerate the development of the suite of personalised medicine diagnostics.

Back to list

Recent Jobs